| 日付 |
タイトル |
| 2023/11/14 |
イルミナが今後の投資家向けカンファレンスをウェブキャスト |
| 2023/11/13 |
イルミナは、低中所得国における病原体シーケンスの加速をサポートするグローバルヘルスアクセスイニシアチブを開始 |
| 2023/11/01 |
イルミナ、固形がんの包括的ゲノムプロファイリングを可能にする新しいリキッドバイオプシーアッセイを発売 |
| 2023/10/13 |
Illumina responds to European Commission's divestiture order |
| 2023/10/11 |
Illumina Posted a Stewardship-Focused Presentation for Investors |
| 2023/10/05 |
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023 |
| 2023/09/29 |
イルミナ、医療機器として最高レベルのハイスループットシーケンサーNovaSeq™ 6000Dxシステムの登録を完了 |
| 2023/09/05 |
イルミナの取締役会、Jacob Thaysen博士を新しい最高経営責任者に任命 |
| 2023/08/28 |
イルミナが今後の投資家会議をウェブキャスト |
| 2023/08/17 |
イルミナがソリューションセンターを開設し、インドのゲノミクス能力を拡大 |
| 2023/08/11 |
イルミナが今後の投資家会議をウェブキャスト |
| 2023/08/09 |
Steven Barnard博士が最高技術責任者に任命 |
| 2023/08/09 |
イルミナ、2023年第2四半期の決算を発表 |
| 2023/07/25 |
イルミナとピラーバイオサイエンスが提携し、個別化がん治療オプションへのアクセスを改善 |
| 2023/07/18 |
Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 |
| 2023/07/18 |
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck |
| 2023/07/11 |
Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery |
| 2023/06/11 |
Illumina announces CEO transition plan |
| 2023/06/05 |
Illumina releases 2022 Corporate Social Responsibility Report |
| 2023/06/02 |
Illumina's Board of Directors elects two experienced Independent Directors to Board |
| 2023/06/01 |
Illumina unveils AI software to predict disease-causing genetic mutations in patients |
| 2023/05/31 |
Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023 |
| 2023/05/30 |
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing |
| 2023/05/25 |
Illumina announces preliminary results of annual meeting |
| 2023/05/18 |
Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees |
| 2023/05/16 |
Illumina's genomic technologies enable better pathogen preparedness and response |
| 2023/05/15 |
Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience |
| 2023/05/12 |
Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees |
| 2023/05/08 |
Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan" |
| 2023/05/02 |
Illumina increases equitable access to STEM education, reaching over 1 million learners |
| 2023/05/01 |
Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card |
| 2023/04/25 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth |
| 2023/04/20 |
Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees |
| 2023/04/12 |
Illumina's cloud-based informatics programs recognized for robust, international data privacy protections |
| 2023/04/11 |
Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients |
| 2023/04/05 |
Illumina celebrates 25 years of innovation |
| 2023/04/04 |
Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023 |
| 2023/04/04 |
Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023 |
| 2023/04/03 |
Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024 |
| 2023/03/30 |
Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee |
| 2023/03/27 |
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease |
| 2023/03/24 |
Illumina Issues Statement in Response to Carl Icahn's Letter |
| 2023/03/20 |
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements |
| 2023/03/14 |
Illumina launches its first product enabling long- and short-read sequencing on one instrument |
| 2023/03/13 |
Illumina Responds to Icahn Partners' Nomination of Directors |
| 2023/03/02 |
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States |
| 2023/02/28 |
イルミナ、日本法人ゼネラルマネージャーを任命 |
| 2023/02/27 |
Illumina To Webcast Upcoming Investor Conference |
| 2023/02/08 |
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute |
| 2023/02/07 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022 |
| 2023/02/01 |
Illumina Appoints Joydeep Goswami Chief Financial Officer |
| 2023/01/10 |
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 |
| 2023/01/09 |
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen |